Amflutizole

Amflutizole

SCHEMBL29400347

Nc1c(-c2cccc(C(F)(F)F)c2)nsc1C(=O)O

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
RORB Q92753 8/20 0.48
PDGFRB P09619 1/20 0.47
KDR P35968 1/20 0.47
ADORA1 P30542 3/20 0.47
ADORA2A P29274 2/20 0.47
KMO O15229 2/20 0.46
RORC P51449 1/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
XDH P47989 1/20 0.43
PIN1 Q13526 1/20 0.43
KIF11 P52732 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Amflutizole SCHEMBL395613 1.00 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2RORBPDGFRBKDR
SCHEMBL11000020 0.90 KDR (0.53) ALDH1A1SMN1; SMN2RORBPDGFRBKDR
SCHEMBL8843374 0.87 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2RORBPDGFRBKDR
SCHEMBL11002986 0.85 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2RORBPDGFRBKDR
SCHEMBL8843382 0.85 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2RORBPDGFRBKDR
SCHEMBL11002450 0.85 RORB (0.49) ALDH1A1SMN1; SMN2RORBPDGFRBKDR
SCHEMBL11002573 0.84 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2RORBPDGFRBKDR
SCHEMBL11003650 0.84 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2RORBPDGFRBKDR
SCHEMBL11003587 0.84 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2RORBPDGFRBKDR
SCHEMBL8842879 0.83 MKNK1 (0.48) ALDH1A1KDM4EKIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4706683-A2 CHEWABLE FORMULATIONS Elanco Tiergesundheit AG (CH) 2026-03-11 EP disclosed
US-20230277448-A1 CHEWABLE FORMULATIONS ELANCO TIERGESUNDHEIT AG (CH) 2023-09-07 US disclosed
EP-4208155-A1 CHEWABLE FORMULATIONS Elanco Tiergesundheit AG (CH) 2023-07-12 EP disclosed
CN-115038451-A Multimodal compositions and methods of treatment 阿奎斯蒂弗医疗股份有限公司 2022-09-09 CN disclosed
WO-2022049149-A1 CHEWABLE FORMULATIONS ELANCO TIERGESUNDHEIT AG (CH) 2022-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230277448-A1 CHEWABLE FORMULATIONS SI, TAS2R39, TAS2R31 ALDH1A1 4640/4885SMN1; SMN2 1968/4885RORB 4407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.